Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

AVArx vs Hims

AVArx and Hims sell different medications; this is what separates them.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed
AVArx logo

AVArx

4.8
★★☆☆☆2.4/5

Best for: coverage in all 50 states, which most sellers will not confirm

Visit AVArx →
VS
Hims logo

Hims

6.8
★★★☆☆3.4/5

Best for: knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC

Visit Hims →

If you are choosing between AVArx and Hims, price alone will not settle it. Hims leads our six-part score, 6.8 to 4.8. One of the two has an FDA warning letter on record, covered below.

AVArx vs Hims price

Hims publishes $199 a month. AVArx does not post a GLP-1 price we can quote, so you would only learn its cost after an intake.

Medications and formats

Hims lists semaglutide and tirzepatide; AVArx does not name its drug.

On format, AVArx posts no priced format, while Hims prices compounded injections and brand-name pens.

If you want the FDA-approved brand rather than a compounded version, Hims is the only one of the two with a brand-name price.

Where each one treats patients

AVArx lists 50 states, and Hims lists 50 states.

They overlap in 50 states.

Pricing

AVArx

Pricing not publicly listed.

Hims

StartingCompounded
$199/mo
semaglutide
StartingBrand-name
$299/mo
tirzepatide

Brand Zepbound from $299/mo medication-only; requires Hims Weight Loss Membership ($149/mo)

What each price covers

Hims' price also covers the medication itself, which AVArx does not claim.

AVArx does not say what its price includes.

Hims is silent on shipping and lab work.

That matters most for the drug: unless AVArx confirms otherwise, budget for medication on top of its listed price.

AVArx

Inclusions not disclosed.

Hims

Covered by the monthly price

Medication

In the price

Clinician visits

Charged on top

Shipping

Not stated

Lab work

Not stated

Coaching

Charged on top

Where each one scores higher

Overall, Hims scores 6.8 and AVArx 4.8 out of 10.

AVArx is stronger on support (5.0 vs 3.0).

Hims is stronger on effectiveness (10.0 vs 5.0), user experience (8.0 vs 2.5) and trust & safety (7.0 vs 6.0).

Value and accessibility are within half a point.

How we score

AVArx

4.8/10

Overall

Hims

6.8/10

Value25%

3.0A
vs
B
3.0

Effectiveness25%

5.0A
vs
B
10.0

User Experience15%

2.5A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
7.0

Accessibility10%

10.0A
vs
B
10.0

Support10%

5.0A
vs
B
3.0

FDA warning letters

The FDA sent Hims a warning letter dated September 9, 2025 (letter 716567), and it is still open.

AVArx has no FDA warning letter on record with us.

Features & Coverage

FeatureAVArxHims
Starting PriceNot published$199/mo
Features✓4 features2 features
States Available5050
Compounded—✓ Yes
Brand Name—✓ Yes
FSA/HSA Accepted✓ Yes—
FDA Warning Letters✓None1 letter

About AVArx

No price is published before intake. The seller is a telehealth technology platform based in Glendale, California, and it routes patients to prescribers at Arora Health & Aesthetics. The offering is GLP-1 and wellness-peptide care.

Read our full AVArx review →

About Hims

Hims is a major men's telehealth brand. Its weight loss offering is compounded semaglutide on a 6-month plan.

Read our full Hims review →

Pros & Cons

AVArx

What we like

  • Serves all 50 states
  • We found no FDA warning letters issued to AVArx
  • A live video visit with a clinician is required before a prescription, which is slower than a form and is the more careful intake

Watch-outs

  • You only see a price after finishing the medical intake, so you cannot compare costs before sharing health information
  • Ask which pharmacy fills the prescription before you pay, so you can check its license

Hims

What we like

  • Shows its price before the medical questionnaire, so you can compare it without handing over health information
  • The monthly price includes the medication
  • Serves all 50 states
  • Names 4 pharmacies that fill its prescriptions, which most sellers do not

Watch-outs

  • Not included in the monthly price: clinician visits, coaching
  • The FDA has issued Hims a warning letter. Read what it alleges: a letter flags a problem but does not by itself rule a seller out
  • Its semaglutide is compounded rather than FDA-approved, so it has not been reviewed by the agency for safety, effectiveness or manufacturing quality

Our Verdict

Winner: Hims

Hims wins this one, 6.8 to 4.8, above all for knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC. AVArx fits better if coverage in all 50 states, which most sellers will not confirm is your priority.

Choose AVArx if…

You want coverage in all 50 states, which most sellers will not confirm.

Choose Hims if…

You want knowing which pharmacy fills the vial: it names Apostrophe Pharmacy LLC and an opening price near $199 a month.

Ready to start? GLP-1 providers we have vetted

Telehealth providers, vetted by us, prescribing GLP-1 online.

Vetted by our editors · no insurance required

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.8

Oak

Semaglutide at $119/month, 37% below the typical price

9.4

Trimi Health

Knowing which pharmacy fills the vial: it names VialsRx

6.4

ShedRx

Oral orforglipron alongside the injectables

AVArx vs Hims: FAQ

Only Hims publishes a price ($199 a month). AVArx quotes after sign-up.
No. AVArx lists no named drug; Hims lists semaglutide and tirzepatide.
Both list 50 states and share 50.
Only Hims includes the medication itself.
AVArx has none. Hims has an open FDA warning letter from September 9, 2025.
No. Neither AVArx nor Hims pays us anything.

Or see the full category ranking.

Novo Nordisk A/S owns the Wegovy®, Ozempic® and Rybelsus® marks; Eli Lilly and Company owns Mounjaro® and Zepbound®. Every other product name and mark on this page belongs to whoever owns it. No pharmaceutical manufacturer is affiliated with GLP Watchdog. See trademark disclaimer.